Crossref
Lactate-driven lysine lactylation in tumor progression, therapy resistance, and prognosis
MedScience · 2026-04 · 20 (2) · 392-395
DOI: 10.1007/s11684-026-1212-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedScience, online erschienen am 30.04.2026. Verfasst von Dan Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Hunan Polytechnic of Environment and Biology, Hengyang, 421005, China. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- School of Medicine, Hunan Polytechnic of Environment and Biology, Hengyang, 421005, China.
- School of Medicine, Hunan Polytechnic of Environment and Biology, Hengyang, 421005, China. 122322157@qq.com.
- Institute of Pharmacy and Pharmacology, College of Pharmacy, University of South China, Hengyang, 421001, China. 2023002046@usc.edu.cn.
Zitieren
APA
Huang, D., Jiang, L., Zhao, Q., & Chen, Z. (2026). Lactate-driven lysine lactylation in tumor progression, therapy resistance, and prognosis. MedScience, 20(2), 392-395. https://doi.org/10.1007/s11684-026-1212-4
Vancouver
Huang D, Jiang L, Zhao Q, Chen Z. Lactate-driven lysine lactylation in tumor progression, therapy resistance, and prognosis. MedScience. 2026;20(2):392-395. doi:10.1007/s11684-026-1212-4
BibTeX
@article{Huang2026,
author = {Huang, Dan and Jiang, Lan and Zhao, Qihui and Chen, Zhe},
title = {Lactate-driven lysine lactylation in tumor progression, therapy resistance, and prognosis},
journal = {MedScience},
year = {2026},
volume = {20},
number = {2},
pages = {392--395},
doi = {10.1007/s11684-026-1212-4}
}
EUVIMED